TG Therapeutics, Inc. (TGTX) Ownership
TGTX ownership summary
as of October 18, 2026- Institutions
- 74.6% of shares outstanding
- Insiders
- 7.47% of shares outstanding
- Shares outstanding
- 153.1M
- Float
- 135.2M shares available to trade
- Short interest
- 28.93% 30.6M shares short
- Days to cover
- 16.50 short interest up 1.6% vs prior month
- Institutions 74.62%
- Insiders 7.47%
- Other investors 17.91%
TGTX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 14.41% | 22.1M | $1.19B | −202,885 (−0.9%) | June 30, 2026 |
| 2 | Vanguard Portfolio Management, LLC | 5.20% | 8.0M | $429.8M | −310,713 (−3.8%) | June 30, 2026 |
| 3 | State Street Corp | 5.09% | 7.8M | $420.2M | −863,295 (−10.0%) | June 30, 2026 |
| 4 | Vanguard Capital Management, LLC | 4.02% | 6.1M | $331.9M | −453,855 (−6.9%) | June 30, 2026 |
| 5 | Geode Capital Management, LLC | 2.38% | 3.6M | $196.6M | +142,300 (+4.1%) | June 30, 2026 |
| 6 | D. E. Shaw & Co LP | 2.22% | 3.4M | $183.5M | +2.8M (+476.4%) | June 30, 2026 |
| 7 | Soleus Capital Management, L.P. | 1.91% | 2.9M | $158.0M | −1.1M (−27.3%) | June 30, 2026 |
| 8 | T. Rowe Price Associates, Inc. | 1.81% | 2.8M | $149.4M | +2.1M (+337.4%) | June 30, 2026 |
| 9 | ClearBridge Advisors, LLC | 1.73% | 2.7M | $143.0M | −560,738 (−17.5%) | June 30, 2026 |
| 10 | Congress Asset Management Company, LLP | 1.70% | 2.6M | $140.3M | +432,042 (+19.9%) | June 30, 2026 |
| 11 | Two Sigma Investments LLC | 1.61% | 2.5M | $133.3M | +926,659 (+60.1%) | June 30, 2026 |
| 12 | The Goldman Sachs Group Inc | 1.51% | 2.3M | $124.9M | +26,591 (+1.2%) | June 30, 2026 |
| 13 | Pictet Asset Manangement SA | 1.17% | 1.8M | $96.4M | +38,578 (+2.2%) | June 30, 2026 |
| 14 | Jane Street Group LLC | 1.15% | 1.8M | $94.6M | −289,023 (−14.2%) | June 30, 2026 |
| 15 | Nuveen, LLC | 1.06% | 1.6M | $87.7M | +178,798 (+12.4%) | June 30, 2026 |
| 16 | Morgan Stanley - Brokerage Accounts | 1.05% | 1.6M | $86.4M | +193,544 (+13.7%) | June 30, 2026 |
| 17 | Hood River Capital Management LLC | 1.05% | 1.6M | $86.4M | +31,339 (+2.0%) | June 30, 2026 |
| 18 | Northern Trust Corp | 1.00% | 1.5M | $83.0M | +94,480 (+6.5%) | June 30, 2026 |
| 19 | Charles Schwab Investment Management Inc | 0.86% | 1.3M | $70.9M | +18,048 (+1.4%) | June 30, 2026 |
| 20 | Bank of America Corp | 0.86% | 1.3M | $70.7M | −151,514 (−10.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 7.0M shares and 8 cut 3.9M.
TGTX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 5.52% | 8.4M | $456.0M | +1,779 (+0.0%) | September 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.87% | 4.4M | $236.7M | −5,080 (−0.1%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 2.46% | 3.8M | $203.2M | −43,392 (−1.1%) | September 30, 2026 |
| 4 | Vanguard Small Cap Index | 2.02% | 3.1M | $167.3M | −71,066 (−2.2%) | September 30, 2026 |
| 5 | State Street® SPDR® S&P® Biotech ETF | 1.78% | 2.7M | $146.9M | −51,800 (−1.9%) | September 30, 2026 |
| 6 | Vanguard MStar Small Cap Growth Indx Inv | 1.13% | 1.7M | $93.2M | −92,608 (−5.1%) | September 30, 2026 |
| 7 | Fidelity Small Cap Index | 1.04% | 1.6M | $85.9M | +13,361 (+0.8%) | July 31, 2026 |
| 8 | First Trust NYSE Arca Biotech ETF | 1.04% | 1.6M | $85.5M | — | September 30, 2026 |
| 9 | Vanguard Explorer Inv | 0.91% | 1.4M | $74.8M | +83,483 (+6.4%) | June 30, 2026 |
| 10 | iShares Russell 2000 Growth ETF | 0.89% | 1.4M | $73.5M | −1,724 (−0.1%) | September 30, 2026 |
| 11 | iShares S&P Small-Cap 600 Growth ETF | 0.86% | 1.3M | $70.9M | — | September 30, 2026 |
| 12 | Congress Small Cap Growth Institutional | 0.85% | 1.3M | $70.2M | — | September 30, 2026 |
| 13 | State Street SPDR Port S&P 600 Sm CpETF | 0.84% | 1.3M | $69.7M | — | September 30, 2026 |
| 14 | Pictet-Biotech P USD | 0.73% | 1.1M | $60.5M | +9,858 (+0.9%) | September 30, 2026 |
| 15 | Hood River Small-Cap Growth Instl | 0.61% | 934K | $50.4M | — | June 30, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.55% | 846K | $45.7M | +9,473 (+1.1%) | September 30, 2026 |
| 17 | State Street® SPDR® S&P 600™ Sm Cp GrETF | 0.53% | 817K | $44.1M | — | September 30, 2026 |
| 18 | Vanguard Tax-Managed Small Cap Adm | 0.52% | 800K | $43.2M | −79,545 (−9.0%) | September 30, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.49% | 747K | $40.3M | +504 (+0.1%) | September 30, 2026 |
| 20 | T. Rowe Price Integrated US Sm Gr Eq | 0.47% | 715K | $38.6M | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TGTX insider transactions
latest 3| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-24 | Yann Echelard | Sell | $32.57 | 5,000 | $162,850 |
| 2025-09-11 | Sagar Lonial | Sell | $32.24 | 20,852 | $672,268 |
| 2025-06-13 | Yann Echelard | Sell | $36.94 | 10,000 | $369,400 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TGTX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TGTX
Institutional investors own 74.6% of TG Therapeutics's shares and insiders 7.47%. The largest holder is BlackRock Inc with 14.41% of the shares (22.1M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 8 reduced their stake in the latest filings. Short interest is 28.93% of the float, or 16.50 days of average trading volume. The share count rose 309.5% since 2014.
Related: TGTX analyst forecast, TGTX key metrics. See the TGTX stock overview for the latest quote and news.
TGTX ownership FAQ
Who owns the most TG Therapeutics stock?
The largest shareholders of TG Therapeutics are BlackRock Inc (14.41%), Vanguard Portfolio Management, LLC (5.20%), State Street Corp (5.09%), Vanguard Capital Management, LLC (4.02%), Geode Capital Management, LLC (2.38%).
What percentage of TG Therapeutics is owned by institutions?
Institutions hold 74.6% of TG Therapeutics's shares outstanding; insiders hold 7.47%.
Which funds own TG Therapeutics?
The largest fund holders of TG Therapeutics are iShares Core S&P Small-Cap ETF (5.52%), Vanguard MStar Total Stk Mkt Idx Invest (2.87%), iShares Russell 2000 ETF (2.46%), Vanguard Small Cap Index (2.02%), State Street® SPDR® S&P® Biotech ETF (1.78%).
What is TG Therapeutics's short interest?
30.6M shares of TG Therapeutics were sold short, 28.93% of the float; at the average daily volume it would take 16.50 days to cover.
Are insiders buying or selling TG Therapeutics?
Of the latest 3 reported insider transactions in TG Therapeutics (since June 13, 2025), 0 were purchases and 3 were sales.
How many shares of TG Therapeutics are outstanding?
TG Therapeutics has 153.1M shares outstanding, of which 135.2M are in the public float.